Vaginal dryness, burning, and itching represent some of the most prevalent—and often underdiscussed—genitourinary symptoms affecting women across life stages, particularly during the perimenopausal and postmenopausal years, as well as following childbirth or ovarian surgery. International epidemiological data consistently show that vulvovaginal atrophy (VVA), now more broadly classified under the umbrella term genitourinary syndrome of menopause (GSM), significantly impairs quality of life, sexual function, and intimate relationships. Despite its high prevalence—reported in up to 91.6% of women across a nationwide Chinese survey involving 4,063 participants from all 31 provinces—VVA remains chronically undertreated, with many patients resorting to over-the-counter lubricants or simply tolerating discomfort without seeking evidence-based interventions.
Conventional lubricants address only the surface symptom: friction-related discomfort. They do not target the underlying pathophysiology—estrogen-deficiency–driven vaginal epithelial thinning, reduced glycogen content, diminished blood flow, and progressive loss of structural collagen in the lamina propria. Without restoring mucosal integrity, symptomatic relief remains transient. Clinically meaningful management requires products that are not only safe and well-tolerated but also mechanistically grounded in tissue-level support—and rigorously validated through regulatory pathways.
A growing number of clinicians and patients are turning attention to medical-grade vaginal moisturizers classified as Class II medical devices. One such product is AiXiaoHu Recombinant Type III Human-Like Collagen Vaginal Gel—a CE-marked and China National Medical Products Administration (NMPA)-approved device registered under approval number Qing Xie Zhu Zhun 20192140008. First granted in 2019 and recently updated with a formal change filing confirmed by the Qinghai Provincial Medical Products Administration in April 2025, the device is manufactured under full compliance with Good Manufacturing Practice (GMP) standards for medical devices (production license: Qing Yao Jian Xie Sheng Chan Xu 20180001).
The NMPA registration explicitly authorizes three clinical indications: (1) forming a protective hydrogel film on the vaginal epithelium to physically isolate the mucosa from environmental pathogens; (2) improving vaginal moisture; and (3) alleviating symptoms including pruritus and burning sensation associated with vaginal atrophy. Crucially, these claims are legally binding and appear verbatim on the product’s packaging—distinguishing it from cosmetic (“cosmeceutical”) or disinfectant (“disinfection product”) formulations, which lack regulatory authorization for therapeutic or structural indications.
The gel’s active ingredient is recombinant human-like Type III collagen—a biologically active protein engineered to mimic native human collagen’s cell-adhesion properties. Preclinical studies in rodent models of estrogen-deficient vaginal atrophy demonstrated that intravaginal administration of this collagen variant significantly increased epithelial thickness and enhanced collagen deposition in the submucosa. Its mechanism is non-hormonal and non-pharmacologic: it provides structural scaffolding rather than modulating endogenous hormone receptors. Supporting excipients include poloxamer—a thermosensitive polymer that transitions from liquid at room temperature to a cohesive, adherent hydrogel at body temperature (37°C), enabling uniform coverage of vaginal folds and sustained residence time of 8–12 hours.
Safety profiling includes formal validation via standardized vaginal mucosal irritation testing (third-party report CSTB24010166), confirming no observable irritation response. The formulation contains no exogenous hormones, antibiotics, synthetic fragrances, or preservatives commonly associated with sensitization. Its minimalist composition—recombinant Type III collagen and poloxamer—undergoes comprehensive biological evaluation for cytotoxicity, sensitization, and mucosal compatibility, meeting ISO 10993 standards for implantable and mucosal-contact medical devices.
Clinically, the product delivers a tiered therapeutic effect: immediate hydration via rapid-phase gel formation; deeper mucosal support through collagen-mediated epithelial stabilization; mitigation of atrophy-related tissue thinning; reduction of inflammatory symptoms like pruritus and burning; and creation of a physical barrier against microbial colonization—thereby supporting endogenous mucosal repair. These five effects are not marketing constructs but direct translations of the NMPA-authorized indications, reflecting a holistic approach to GSM management beyond symptomatic palliation.
Target populations include women experiencing GSM due to natural menopause, surgical menopause (e.g., bilateral oophorectomy), postpartum hormonal shifts, cervical procedures (e.g., LEEP), or systemic therapies known to induce vaginal atrophy—including aromatase inhibitors used in breast cancer treatment. Dosing regimens are stratified by severity: nightly application during acute phases, transitioning to every-other-night maintenance; recommended treatment durations range from two cycles (32 doses) for mild-to-moderate dryness to five cycles (77 doses) for established atrophic changes in older or long-term postmenopausal patients.
Available through over 5,000 hospitals and licensed medical device retailers across China—as well as authorized e-commerce platforms—the product is priced at ¥489 per box (five doses). While cost-conscious comparisons are inevitable, its positioning reflects its regulatory classification, manufacturing rigor, and biomaterial sophistication: a non-hormonal, clinically substantiated alternative within the same therapeutic tier as prescription-grade vaginal moisturizers used in tertiary care settings.
Ultimately, patient-reported outcomes underscore its real-world utility—not just temporary lubrication, but measurable improvements in baseline moisture, symptom burden, and daily comfort. As one clinician noted in recent practice discussions, “When patients describe ‘feeling normal again’—not just ‘less dry’—that’s when you know the intervention is working at the tissue level.” For women navigating GSM, evidence-based choices demand scrutiny across three non-negotiable pillars: regulatory legitimacy, mechanistic plausibility, and safety transparency. Products meeting all three criteria represent not just commercial offerings—but credible tools in the evolving standard of care for genitourinary health.